Antibody titres to Campylobacter pylori after treatment for gastritis

• Published in: BMJ Vol. 297; no. 6645; p. 397
• Main Authors: Vaira, D., Holton, J., Cairns, S. R., Falzon, M., Polydorou, A., Dowsett, J. F., Salmon, P. R.
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 06.08.1988; British Medical Association; BMJ Publishing Group LTD
• Subjects: Acute Disease; Antacids - therapeutic use; Antibodies; Antibodies, Bacterial - analysis; Bismuth; Campylobacter; Campylobacter - immunology; Campylobacter Infections; Chronic Disease; Gastritis; Gastritis - drug therapy; Gastritis - etiology; Gastritis - immunology; Gastroenterology; Helicobacter pylori; Histology; Humans; Interval estimators; Organometallic Compounds - therapeutic use; Prospective Studies
• ISSN: 0959-8138; 1468-5833; 1756-1833
• DOI: 10.1136/bmj.297.6645.397

Campylobacter pylori is strongly associated with histologically confirmed gastritis. The most convincing evidence for a pathogenic role of C. pylori in gastritis comes from trials of treatment. The authors investigated the role of C. pylori in dyspeptic patients who had gastritis confirmed by histology by performing a prospective trial with colloidal bismuth subcitrate 240 mg twice daily for four weeks. The authors also report the titres of antibody to C. pylori before and after treatment.